Aptorum Group Limited (NASDAQ:APM, PARIS:APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces completion of the Phase I clinical trial for ALS-4 (a first
Aptorum Group (NASDAQ:APM) reported quarterly losses of $(0.47) per share. This is a 123.81 percent decrease over losses of $(0.21) per share from the same period last year. The company reported $637.78 thousand in